Search 

AEBi was established in the year 2000, and has been managed since then based on the idea that the ability to manipulate and design peptides has vastly superior advantages to many, if not any, existing and trajectory technologies of drug development. This idea is valid today as well.The basic idea is that we do not require a natural lead or a sequence (usually coming from the academia or other research) which are either not strong enough or not specific enough and difficult to manipulate in order to create a drug.
An artificial high complexity pool, representing a broad spectrum of  possibilities, manipulated by our technology, will provide the best possible solution. Such a  solution  will not be hindered or blocked by natural interactions and will be very specific to the problem.
AEBi, a development-stage biopharmaceutical company engaged in discovery and development of therapeutic peptides, has developed a combinatorial biology screening platform technology (IP protected).
The major advantage is that it can be used not only to find binders to known targets, but to select the best functional molecules among them. AEBi's platform is very flexible, exploiting combinatorial biology to discover new and better lead compounds to disease targets.

Our Breakthrough SoAP Platform:
-------------------------------------------------
Our platform provides functional leads to very difficult targets (functional leads - agonist, antagonist, inhibitor, etc.), not merely those that best bind with the target.

Moreover, it allows us to develop drugs to many illnesses, among them CANCER and COVID19, and is expected to transform the drug discovery R&D phase by significantly reducing the attrition rate of new drug candidates.
This Breakthrough technology generates very specific lead compounds with greater functionality and improved pharmacological properties. Such lead Compounds will allow more effective drugs and fewer side effects. The need for such technology is acute and pressing for many reasons. The sole external requirement in the screening process is a Defined Target (usually an illness-related protein).

MuTaTo: our Multiple Targeted Comprehensive Cancer Therapy
-------------------------------------------------------------------------------------
This new cancer treatment is a personalized medicine concept, that can be also turned into a "shelf product". The main principal of it is using multiple targeting peptides connected together with a toxin. The main advantage of it is that it would lower the probability of the targeted cancer cells to develop drug-resistance due to mutations they possess, and at the same time would lower adverse effects due to avidity effect. Each cancer patient would receive a specific drug perfectly suited to his/her cancer, based on the expression profile of receptors on the outer membrane of their cancer cells. This therapy's construct production is easy and rapid. Therefore, the production cost would not be as expensive as with other biological drugs, or other sophisticated cancer treatments.
MuTaTo our Multiple Targeted Safe Cancer Therapy is DIFFERENT and UNIQUE because:
----------------------------------------------------------------
1- It is EFFECTIVE on almost all types of CANCERS because we will develop a MuTaTo molecule for every type of cancers.
2- it is SAFE on healthy cells and DOESN'T cause any suffering to patients.
3- unlike other cancer therapies that attack cancer from only one or 2 targets at most , MuTaTo is DIFFERENT because it attacks cancer from at least 3 targets so that cancer DOESN'T metastasize nor develop drug resistance.
4- MuTaTo can treat almost all types of cancers even rare one and is effective on all cancer stages even terminal ones.
5- our MuTaTo is so versatile it can be:
a) used as personalized Cancer therapy where each cancer patient would receive a specific drug perfectly suited to his/her cancer, based on the expression profile of receptors on the outer membrane of their cancer cells.
b) or it can be mass produced as a "shelf Product - Oncolytic Drug" to treat different cancers with different indications, so we will have not just one MuTaTo Drug, but a COMPLETE FAMILY OF MuTaTo DRUGS, to treat almost all types and indications of Cancers , from all stages, even rare and Terminal cancers.

Our MUTATO Cancer treatment is PATENTED,
https://patents.google.com/patent/WO2018061004A1/en?inventor=Ilan+morad&oq=Ilan+morad

Our PLATFORM is patented
https://patents.google.com/patent/WO2007010525A3/en?inventor=Ilan+morad&oq=Ilan+morad

Our concept is peer approved and we have proof of concept, and published in the prestigious Cancer Therapy Magazine
https://m.scirp.org/papers/98400

-Chinese Journals have written about our concept including MyBioGate
https://mp.weixin.qq.com/s/NYjbJDgdBOtxsAztKr7wMw
独家回访 | 一年内彻底治愈癌症,炒作还是事实？
徐子宜 Ginger 美柏企业服务
here is one article about us in another journal:
https://www.myzaker.com/article/5f88ec9f32ce40ea2900000a

For more than 120 years, the Trade Commissioner Service (TCS) has been helping Canadian companies navigate international markets. Our trade commissioners in more than 160 cities worldwide can provide you with key business insights and access to an unbeatable network of international contacts. The TCS provides Canadian businesses and organizations with tailored advice to help them enter new markets outside of Canada.

Focus-X is a preclinical stage biotech company committed to the discovery and development of personalized precision medicine fulfilling the unmet needs in cancer diagnosis and treatment. We are to release the true potential of radioligand therapy by leveraging our world class peptide drug discovery platform and joining force with top radiopharmaceutical partners.

maintect GmbH was founded 2018 in collaboration with Mainz University Medical Center Germany by ophthalmological scientists.
maintect is developing an innovative antibody treatment for a new target instead of the well-known VEGF in wAMD (wet age-related-macular-degeneration, one of the most frequent causes of blindness). This new antibody will help the patients who don’t benefit from anti-VEGF treatment and all others. maintect applied already for patent in several countries. Combination with anti-VEGF is also an option. In parallel, the company is developing a companion diagnostic kit using lateral flow assays for anti-VEGF treatment in wAMD. This test will determine which patients will benefit most from the new treatment and will facilitate the market entrance. Furthermore, the company is interested in contract research and collaborations in building diagnostic kits.

MEDGENE is a T cell therapy biotech start-up (late pre-clinical stage) based in Maryland, USA.

- Focused on developing PD1+ peripheral blood-derived, tumor-reactive CD8+ T cell (PBTL) therapies as a platform for the treatment of solid tumors that are rare, orphan, and have critical (high) unmet need
- PBTL is a simpler, smarter version of TIL 
- PBTL is a process to select highly tumor-reactive T cells from a patient's peripheral blood based on the expression of two specific T cell surface markers: PD-1 and/or TIM-3 

- After selection, expanded to large quantities, it gets re-infused into the patient via the ACT regimen

- PBTL technology has been patented (issued) already in the US, China, the EU, Japan, Australia 
- MEDGENE has robust Clinical Development Pipelines (currently, 9 as monotherapy way)

- Looking for funding for entering Phase 1/2 in three pipelines in the US

- Looking for partnering for the Asian market (China, Japan, South Korea)

Mission Bio unlocks the ground truth of cancer through response, relapse, and remission with its Tapestri Platform, powered by single-cell multi-omics. As the first and only to analyze genotype and phenotype simultaneously in single cells, the Tapestri Platform can help unravel the inherent complexity of cancer. The technology discerns key biomarkers to stratify patients more precisely, signal treatment resistance as it begins, and predict relapse for better patient outcomes. Application areas include blood cancers, solid tumors, and genome editing validation.

Researchers at Memorial Sloan Kettering Cancer Center (MSK), MD Anderson Cancer Center (MDACC), and the University of California at San Francisco (UCSF) have leveraged the Tapestri Platform to support their research for characterizing clonal dynamics in a variety of cancers, identifying minimal residual disease (MRD), and monitoring treatment response and therapy resistance. The company’s award-winning technology is also leveraged by LabCorp and Agios to enable more efficient clinical trials.

MSL Pharma is an early-stage pharma company that performs ideation, analysis and identification of the underlying pathological pathways to determine how to treat diseases. The Company holds exclusive licenses from the Hebrew University & Ben-Gurion University of the Negev. There are data, patents and publications concerning the technologies.

As an early-stage company, in order to reduce overhead costs, we effectively act as the project manager – we plan the assays and subcontract the early development stages to university labs, and the later stages to CROs that specialize in the different fields. The Company monitors the results, determines next steps and fundraises for the next phases of development. We believe that working with leading experts at CROs is critical for success.

The Company has licenses for platform technologies which are progressing to several different projects; as such it is planning to out-license at various stages of development.

Synthesis of cyclic peptides which are peptidomimetics
MSL Pharma has the capability to identify “active regions” of proteins and peptides, to isolate them and to turn them into cyclic peptides which are selective for the desired receptors and stable, thereby preventing off-target activation and adverse effects (see Asset, Table 1).

Drug delivery systems for peptides and other molecules
MSL Pharma has two technologies for drug delivery (see Mode of Delivery, Table 1) that achieve unprecedented bioavailability:
1. Lipophilic prodrug charge masking (LPCM) technology for the oral delivery of peptides. This technology makes a chemical modification in a peptide to be converted to oral delivery, to produce a prodrug of this peptide. This causes it to be absorbed through the intestinal cell and once the prodrug enters the blood stream, it converts back to the original peptide. Typically, the Pgp Efflux system limits the prodrug absorption; we have overcome this with an approved self-assembling PNL (pro-nano liposphere) encapsulation system, itself a self-nanoemulsifying drug delivery system (SNEDDS), which increases prodrug solubility and inhibits the Pgp Efflux system.

2. A novel nanoparticle formulation called AmyloLipid Nanovesicles which is constructed of natural materials and therefore safe ,biodegradable and has an advantage for the delivery of peptides. This technology is used also for the delivery of other molecules, can be used for nose-to-brain, sublingual, transdermal and probably also oral delivery, and can be applied to our assets (Table 1) or existing assets (Table 2).

A novel smart multi-armed linker for targeted drug delivery
Our linker can be used for peptide-drug conjugates (PDCs), antibody-drug conjugates (ADCs) and nanoparticle-drug conjugates (NDCs). Our linker releases the payload (chemotherapeutic drug or fluorescent) only in the tumor cells and can bind up to three payloads (see Table 3). We have demonstrated that using two or three different drug payloads kills the tumor cells more potently and with less drug resistance developing.

Discovery of novel peptides for peptide-drug conjugates
We have technologies to synthesize novel peptides which will bind to receptors overexpressed in certain tumors so that we will be able to use them for synthesizing peptide-drug conjugates (PDCs) to diagnose and treat different tumors. We already have at our disposal peptides that bind to the five different somatostatin receptors (overexpressed in pancreatic, gallbladder, breast, ovary, prostate, melanoma, lymphoma, glioblastoma, colon and non-small-cell lung tumors) and to certain integrin receptors (overexpressed in tumors such as breast, glioblastoma, leukemic cells). 

We are a corporate finance firm committed to advancing the field of Healthcare through advisory,and investments.

We advise and buy-side and sell side corporates and Family offices on investment in Healthcare & life Sciences across Switzerland, Europe and the US.

REM Analytics is a research and development service organisation, helping our customers develop and commercialise new products fast.
Having developed a series of core proprietary technologies, we deploy them to guarantee our customers the shortest time from concept to market. Our areas of focus are the development of personalised nutrition solutions, active food ingredients, functional cosmetics and agriculture.